Volume 5 Number 1 2026
Next-Generation Nanomedicine: Emerging Technologies and the Future of Personalized Healthcare
Adam Shah Abdul Majid 1*, Chahat Antil 2, Natasha Phelps 2
Biosensors and Nanotheranostics 5 (1) 1-8 https://doi.org/10.25163/biosensors.5110984
Submitted: 09 May 2026 Revised: 01 May 2026 Accepted: 07 May 2026 Published: 09 May 2026
Nanomedicine has moved a long way from its first liposomal products. What began as an effort to keep poorly soluble drugs in circulation is now an attempt to engineer, at the nanoscale, carriers that recognise diseased cells, sense their surroundings and release a payload only when conditions are right. This narrative review traces that shift and asks how far it has actually travelled toward the clinic. We synthesised peer-reviewed sources published between 2011 and 2026, organised around four themes. First, the move from passive, Enhanced Permeability and Retention (EPR)-based accumulation, which often delivers well under a tenth of the injected dose to tumours, toward chemo-biochemical convergence: ligand-directed, stimulus-responsive platforms that couple synthetic chemistry with biological recognition. Second, physical and micro-engineered vectors, including quantum biosensors embedded in organ-on-a-chip systems and wearable or implantable BioMEMS that permit continuous, label-free monitoring. Third, computational integration, in which multi-omics profiling, machine learning and physiologically based pharmacokinetic models converge in patient-specific digital twins. Fourth, disease-specific applications in oncology, notably copper-driven cuproptosis in hepatocellular carcinoma, and in brain disorders where the blood-brain barrier remains the decisive obstacle. Across these themes the engineering is impressive, yet the evidence is uneven. Protein corona formation, batch-to-batch variability, long-term safety and drug-device regulatory pathways continue to limit translation, and most digital twins remain unvalidated. We argue that progress now depends less on new materials than on standardised characterisation, prospective validation and early regulatory engagement, and we sketch a roadmap toward that goal.
Keywords: nanomedicine; chemo-biochemical convergence; stimuli-responsive nanocarriers; quantum biosensors; organ-on-a-chip; BioMEMS; digital twins; precision medicine; clinical translation
Akwo, A. U., et al. (2026). Nanobiotechnology: Precision medicine and targeted drug delivery. Next Nanotechnology, 9, 100493.
AlSuhaimi, S. A., et al. (2026). Silica nanoparticles in nanomedicine: Evolution from synthesis control to biological identity, clearance-aware design, and translation: A fundamental review. Next Nanotechnology, 10, 100802.
Bhukta, P., et al. (2026). Nanomedicine approaches for Alzheimer's disease: Advances in drug delivery and theranostic applications. Next Nanotechnology, 9, 100495.
Boisseau, P., & Loubaton, B. (2011). Nanomedicine, nanotechnology in medicine. Comptes Rendus Physique, 12(7), 620-636.
Chowdhury, S., Sarkar, S., & Das, A. (2026). Digital twins and nanomedicine: Predictive modelling for clinical translation. Next Nanotechnology, 10, 100688.
Deshmukh, S. S., & Yadav, K. S. (2025). Next-generation nanocarriers, AI, and digital twin systems within an integrated cancer therapy framework. Next Nanotechnology, 8, 100286.
Fornaguera, C., & García-Celma, M. J. (2017). Personalized nanomedicine: A revolution at the nanoscale. Journal of Personalized Medicine, 7(4), 12.
Haque, A., Khan, T., Islam, R. U., & Naseem, S. (2025). Nanomedicine breakthroughs in cancer and neurodegenerative disease therapy. Next Nanotechnology, 8, 100233.
Kanipandian, N., et al. (2026). Nanotechnology for diabetes management and biomedical innovations. Next Nanotechnology, 10, 100595.
Labhade, S., & Pihulkar, C. (2026). Nanotechnology-enabled targeting of cuproptosis in hepatocellular carcinoma: Emerging nanomedicine strategies for mitochondrial metabolic therapy. Next Nanotechnology, 10, 100769.
Laddha, U. D., et al. (2026). AI-driven smart systems and biosensors in personalized drug delivery. Next Nanotechnology, 10, 100581.
Marinescu, M.-R., Ionescu, O. N., Pachiu, C. I., Dinescu, M. A., Muller, R., & Suchea, M. P. (2025). Next-gen healthcare devices: Evolution of MEMS and BioMEMS in the era of the Internet of Bodies for personalized medicine. Micromachines, 16(11), 1182.
Marriam, S., & Khalid, G. E. R. (2026). The chemo-biochemical convergence in nanomedicine: A review of tailored therapeutic strategies. Next Nanotechnology, 9, 100371.
Mazahir, F. (2026). Precision nanomedicines in glioblastoma therapy and challenges remain. Next Nanotechnology, 9, 100431.
Payam, A. F., & Lionadi, I. (2026). Approved cancer nanomedicines highlight formulation strategies and clinical translation challenges. ACS Nano Medicine, 1(8), 871-911.
Preetam, S. (2026). Integration of quantum biosensors into microfluidic organ-on-a-chip platforms toward real-time high-resolution biomedical monitoring. Next Nanotechnology, 10, 100632.
Reddy, B. N., Saravanan, S., Manjunath, V., & Reddy, P. R. S. (2024). Review on next-gen healthcare: The role of MEMS and nanomaterials in enhancing diagnostic and therapeutic outcomes. Biomaterials Connect, 1, 2024.0004.
Tiwari, P. K., et al. (2026). Regulatory challenges and translational readiness of nanocarrier-based drug delivery systems. Next Nanotechnology, 10, 100642.
Host–Microbiome Co-Evolution in Inflammatory Bowel Disease: Integrative Insights into Genetic Susceptibility, Strain-Level Adaptation, and Immunometabolic Signalling
Engineered Extracellular Vesicles Escape Endosomal Trapping to Deliver Alzheimer's Therapeutics Across the Blood-Brain Barrier
Stimuli-Responsive Nanocarriers Reprogram the Rheumatoid Joint but Outpace Clinical Manufacturing